Results 201 to 210 of about 2,204,237 (310)

Steady Decline of HBV DNA Load under NAs in Lymphoma Patients and a Higher Level of qAnti-HBc Predict HBV Reactivation. [PDF]

J Clin Med, 2023
Liu Y, Nuersulitan R, Zhang C, Huo N, Li J, Song Y, Zhu J, Liu W, Zhao H.   +8 more
europepmc   +1 more source

Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma

Liver international (Print), 2015
C. Saitta, G. Tripodi, A. Barbera, A. Bertuccio, A. Smedile, A. Ciancio, G. Raffa, A. Sangiovanni, G. Navarra, G. Raimondo, T. Pollicino   +10 more
semanticscholar   +1 more source

A Quantitative Systems Pharmacology (QSP) Model of Acute Hepatitis B Virus Infection: Mechanistic Insights and Foundations for Future Extensions

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Chronic hepatitis B virus (HBV) infection remains a significant global health challenge. While the dynamic interplay between viral replication and host immune responses determines infection outcomes, the mechanisms driving the resolution of acute infection versus the emergence of chronicity remain incompletely understood.
Clémence Boivin‐Champeaux, Stephan Schmidt, Scott Balsitis, Francine Johansson Azeredo, Justin S. Feigelman   +4 more
wiley   +1 more source

HBV DNA integration gene CCDC91 is oncogenic and a potential therapeutic target for hepatocellular carcinoma. [PDF]

Commun Biol
Li M, Wu S, Luo H, Niu J, Fang Y, Chen W, Cao L, He Y.   +7 more
europepmc   +1 more source

High-sensitivity HBV DNA test for the diagnosis of occult HBV infection: commonly used but not reliable. [PDF]

Front Cell Infect Microbiol, 2023
Wang C, Xue R, Wang X, Xiao L, Xian J.
europepmc   +1 more source

Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy

United European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Chronic delta hepatitis represents a major health burden. Until recently, pegylated interferon‐alfa‐2a (PEG‐IFNα) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). The aim of this study was to evaluate 10‐year long‐term clinical and virological outcomes after 96 weeks of treatment with PEG ...
Cihan Yurdaydin, Julia Kahlhöfer, Florin Alexandru Caruntu, Kendal Yalcin, Selim Gürel, Ulus S. Akarca, Kathrin Sprinzl, Hans H. Bock, Jan‐Hendrik Bockmann, George V. Papatheodoridis, Uta Merle, Münevver Demir, Svenja Hardtke, Onur Keskin, Ramazan Idilman, Markus Cornberg, Heiner Wedemeyer, Anika Wranke   +17 more
wiley   +1 more source

HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study. [PDF]

Sci Rep
Liang Z, Lei J, Li H, Dai H, Zhang Y, Wang F, Ma W, Yu H, Chen X, Kong Q, Zhao J, Lu Y.   +11 more
europepmc   +1 more source

Two fragments of HBV DNA integrated into chrX: 11009033 and its genetic regulation in HepG2.2.15. [PDF]

Mol Med Rep, 2023
Ruan P, Zhou R, He C, Huang C, Lin M, Yin H, Dai X, Sun J.   +7 more
europepmc   +1 more source

Exacerbation of Anti‐Cytomegalovirus Immunity and Mobilization of γ9δ1 T Cells During the Acute Phase of Hepatitis E Virus Infection

Microbiology and Immunology, Volume 70, Issue 2, Page 113-124, February 2026.
ABSTRACT HEV causes chronic infections that are detrimental to immunocompromised patients. Previous studies showed alterations of γδ T cell subsets at the acute phase of HEV infection. To assess a possible role of CMV, we have examined the frequencies and responses to CMV and HEV of blood γδ T cell subsets from control donors and acute‐phase HEV ...
Marion Retailleau, Fanny Martini, Florence Abravanel, Nassim Kamar, Jacques Izopet, Eric Champagne   +5 more
wiley   +1 more source

Reevaluating antiviral thresholds in HBV DNA-negative inactive HBsAg carriers: a multicenter histopathological analysis. [PDF]

Virol J
Ren S, Zheng S, Zhang X, Fu J, Fan R, Ruan Q, Huang W, Gao H, Xue X, Yang F, Xie Y, Li M, Chen X.   +12 more
europepmc   +1 more source